Bronchiectasis Epidemiology Forecast

List of Tables

Bronchiectasis Insights and Trends

Bronchiectasis is a chronic lung disease characterized by permanent dilation and damage of the bronchial tubes, leading to impaired mucus clearance, chronic cough, and recurrent lung infections. The condition involves irreversible structural damage, creating a cycle of inflammation and infection that affects lung function and quality of life. Risk factors include prior respiratory infections such as pneumonia and tuberculosis, chronic lung diseases, cystic fibrosis, autoimmune disorders, immune deficiencies, among others.
According to DelveInsight's analysis, as of 2025, the total diagnosed prevalent cases of bronchiectasis across the 7MM is estimated at approximately 1,150,000.
The broader bronchiectasis cohort is epidemiologically split into CFB (Cystic Fibrosis Bronchiectasis), caused by a specific inherited genetic mutation with systemic multi-organ impact, and NCFB (Non-Cystic Fibrosis Bronchiectasis), a diverse cohort where permanent airway damage stems from non-genetic etiologies like infections or autoimmune diseases.
A major challenge in the bronchiectasis landscape is the widespread delay in initial identification, which often allows substantial disease progression and structural lung damage to occur entirely unmonitored. Because early clinical manifestations frequently overlap with more common respiratory conditions, a high number of patients remain undiagnosed during the critical early phases of the disease.

DelveInsight's 'Bronchiectasis-Epidemiology Forecast - 2036' report delivers an in-depth understanding of bronchiectasis, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Geography Covered:

North America: The United States

Europe: Germany, France, Italy, Spain and the United Kingdom

Asia-Pacific: Japan

Bronchiectasis Understanding

Bronchiectasis Overview and Diagnosis

Bronchiectasis is a chronic lung disease characterized by permanent dilation and damage of the bronchial tubes, leading to impaired mucus clearance, chronic cough, and recurrent lung infections. The condition involves irreversible structural damage, creating a cycle of inflammation and infection that affects lung function and quality of life. Risk factors include prior respiratory infections such as pneumonia and tuberculosis, chronic lung diseases, cystic fibrosis, autoimmune disorders, immune deficiencies, among others.

Bronchiectasis is primarily diagnosed using high-resolution computed tomography (HRCT) of the chest, which is the gold-standard imaging technique for identifying permanent bronchial dilatation and airway wall thickening. The diagnostic workup also includes a detailed clinical history, physical examination, pulmonary function tests (PFTs), and sputum culture to assess lung function and detect chronic airway infections. Additional laboratory tests, such as immunoglobulin levels, autoimmune screening, and evaluation for underlying conditions like cystic fibrosis or allergic bronchopulmonary aspergillosis, may be performed to determine the cause and guide management.

Bronchiectasis Epidemiology

Key Findings from Bronchiectasis Epidemiological Analysis and Forecast

As of 2025, the total diagnosed prevalent cases of NCFB across the 7MM is estimated at approximately 1,100,000 cases, reflecting the substantial burden of NCFB and the variability in diagnostic practices across geographies.
The gender-specific diagnosed prevalent cases of CFB across the 7MM were estimated at approximately 42,000 cases in males and 38,000 cases in females in 2025, consistent with the broadly comparable gender distribution observed in CF populations.
In 2025, the microbiology-specific diagnosed prevalent cases of Pseudomonas aeruginosa in CFB patients across the 7MM were estimated at approximately 21,500 cases

Industry Experts and Physician Views for Bronchiectasis

To keep up with bronchiectasis dynamic epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the bronchiectasis epidemiology, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 6+ KOLs to gather insights at country level. Centers such as the University of Santo Tomas, Berlin Institute of Health at Charite , Paris-Est Creteil University, UCL Queen Square Institute of Neurology etc. were contacted.

Their opinion helps understand, validate, highlight and provide epidemiological context in Bronchiectasis.

Scope of the Report:

The report covers a segment of an executive summary, a descriptive overview of bronchiectasis, explaining their causes, signs and symptoms and pathogenesis.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along diagnostic guidelines.
The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
A detailed review of current challenges in establishing the diagnosis.

Report Insights

Bronchiectasis Patient Population Forecast

Report Key Strengths

Epidemiology-based (Epi-based) Bottom-up Forecasting
11-year forecast
Patient Burden Trends (by geography)
The 7MM Coverage

FAQs:

Epidemiology Insights

What is the forecast period covered in the report?
How is epidemiological data collected and analyzed for forecasting purposes?
Out of all EU4 countries and the UK, which country had the highest population of bronchiectasis cases?
What are the disease risks and burdens of bronchiectasis?
At what compound annual growth rate the population is expected to grow across the 7MM during the forecast period?
What would be the forecasted patient population of bronchiectasis at the 7MM level?

Reasons to Buy:

The report will help in developing business strategies by understanding the latest epidemiology trends.
Insights on patient burden/ prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand KOLs' perspectives on the dynamic epidemiology trends.
This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Product Code: DIEI0502

1. Key Insights

2. Report Introduction

3. Epidemiology Overview at a Glance

3.1. Patient Share (%) Distribution of Bronchiectasis in the 7MM in 2025
3.2. Patient Share (%) Distribution of Bronchiectasis the 7MM in 2036

4. Epidemiology Forecast Methodology

5. Executive Summary

6. Disease Background and Overview: Bronchiectasis

6.1. Introduction
6.2. Types of Bronchiectasis
6.3. Clinical Manifestations
6.4. Etiology
6.5. Risk Factors
6.6. Symptoms
6.7. Pathophysiology
6.8. Biomarkers
6.9. Diagnosis
- 6.9.1. Differential Diagnosis
- 6.9.2. Diagnostic Algorithm

7. Patient Journey

8. Epidemiology and Patient Population

8.1. Key Findings
8.2. Assumptions and Rationale
- 8.2.1. Diagnosed Prevalent Cases of NCFB
- 8.2.2. Diagnosed Prevalent Cases of CFB
8.3. Total Diagnosed Prevalent Cases of Bronchiectasis in the 7MM
8.4. The United States
- 8.4.1. Total Diagnosed Prevalent Cases of CFB in the US
- 8.4.2. Gender-specific Diagnosed Prevalent Cases of CFB in the US
- 8.4.3. Age-specific Diagnosed Prevalent Cases of CFB in the US
- 8.4.4. Microbiology of CFB Patients in the US
- 8.4.5. Total Diagnosed Prevalent Cases of NCFB in the US
- 8.4.6. Gender-specific Diagnosed Prevalent Cases of NCFB in the US
- 8.4.7. Severity-specific Diagnosed Prevalent Cases of NCFB in the US
- 8.7.8. Etiology-specific Diagnosed Prevalent Cases of NCFB in the US
- 8.7.9. Microbiology of NCFB Patients in the US
8.5. EU4 and the UK
- 8.5.1. Total Diagnosed Prevalent Cases of CFB in EU4 and the UK
- 8.5.2. Gender-specific Diagnosed Prevalent Cases of CFB in EU4 and the UK
- 8.5.3. Age-specific Diagnosed Prevalent Cases of CFB in EU4 and the UK
- 8.5.4. Microbiology of CFB Patients in EU4 and the UK
- 8.5.5. Total Diagnosed Prevalent Cases of NCFB in EU4 and the UK
- 8.5.6. Gender-specific Diagnosed Prevalent Cases of NCFB in EU4 and the UK
- 8.5.7. Severity-specific Diagnosed Prevalent Cases of NCFB in EU4 and the UK
- 8.5.8. Etiology-specific Diagnosed Prevalent Cases of NCFB in EU4 and the UK
- 8.5.9. Microbiology of NCFB Patients in EU4 and the UK
8.6. Japan
- 8.6.1. Total Diagnosed Prevalent Cases of CFB in Japan
- 8.6.2. Gender-specific Diagnosed Prevalent Cases of CFB in Japan
- 8.6.3. Age-specific Diagnosed Prevalent Cases of CFB in Japan
- 8.6.4. Microbiology of CFB Patients in Japan
- 8.6.5. Total Diagnosed Prevalent Cases of NCFB in Japan
- 8.6.6. Gender-specific Diagnosed Prevalent Cases of NCFB in Japan
- 8.6.7. Severity-specific Diagnosed Prevalent Cases of NCFB in Japan
- 8.6.8. Etiology-specific Diagnosed Prevalent Cases of NCFB in Japan
- 8.6.9. Microbiology of NCFB Patients in Japan

9. Key Opinion Leaders' Views

9.1. Expert/KOL Interview Highlights

10. Appendix

10.1. Bibliography
10.2. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

Product Code: DIEI0502

List of Tables

Table 1: Summary of Epidemiology (2022-2036)
Table 2: Key Events for Bronchiectasis
Table 3: Etiology of Bronchiectasis
Table 4: Risk Factors of Bronchiectasis
Table 5: Key to evidence statements and grades of recommendations
Table 6: Key to evidence statements and grades of recommendations
Table 7: Comparison of Guideline Recommendations in Different Bronchiectasis Guidelines
Table 8: Total Diagnosed Prevalent Cases of NCFB in the 7MM (2022-2036)
Table 9: Total Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in the 7MM (2022-2036)
Table 10: Total Diagnosed Prevalent Cases of NCFB in the US (2022-2036)
Table 11: Gender-specific Diagnosed Prevalent Cases of NCFB in the US (2022-2036)
Table 12: Severity-specific Diagnosed Prevalent Cases of NCFB in the US (2022-2036)
Table 13: Etiology-specific Diagnosed Prevalent Cases of NCFB in the US (2022-2036)
Table 14: Microbiology of NCFB Patients in the US (2022-2036)
Table 15: Total Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in the US (2022-2036)
Table 16: Gender-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in the US (2022-2036)
Table 17: Age-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in the US (2022-2036)
Table 18: Microbiology of Cystic Fibrosis Bronchiectasis Patients in the US (2022-2036)
Table 19: Total Diagnosed Prevalent Cases of NCFB in EU4 and the UK (2022-2036)
Table 20: Gender-specific Diagnosed Prevalent Cases of NCFB in EU4 and the UK (2022-2036)
Table 21: Severity-specific Diagnosed Prevalent Cases of NCFB in EU4 and the UK (2022-2036)
Table 22: Etiology-specific Diagnosed Prevalent Cases of NCFB in EU4 and the UK (2022-2036)
Table 23: Microbiology of NCFB Patients in EU4 and the UK (2022-2036)
Table 24: Total Diagnosed Prevalent Cases of NCFB in EU4 and the UK (2022-2036)
Table 25: Gender-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in EU4 and the UK (2022-2036)
Table 26: Age-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in EU4 and the UK (2022-2036)
Table 27: Microbiology of Cystic Fibrosis Bronchiectasis Patients in EU4 and the UK (2022-2036)
Table 28: Total Diagnosed Prevalent Cases of NCFB in Japan (2022-2036)
Table 29: Gender-specific Diagnosed Prevalent Cases of NCFB in Japan (2022-2036)
Table 30: Severity-specific Diagnosed Prevalent Cases of NCFB in Japan (2022-2036)
Table 31: Etiology-specific Diagnosed Prevalent Cases of NCFB in Japan (2022-2036)
Table 32: Microbiology of NCFB Patients in Japan (2022-2036)
Table 33: Total Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in Japan (2022-2036)
Table 34: Gender-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in Japan (2022-2036)
Table 35: Age-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in Japan (2022-2036)
Table 36: Microbiology of Cystic Fibrosis Bronchiectasis Patients in Japan (2022-2036)

List of Figures

Figure 1: Symptoms of Exacerbation for Bronchiectasis
Figure 2: Graphical Explanation of the Vicious Cycle Theory, Which Renders Damaged Lung Epithelium Susceptible to Further Infections
Figure 3: Pathophysiology of an Airway With Bronchiectasis
Figure 4: Common Microbes Which may Cause Infections in Bronchiectasis
Figure 5: Algorithm for the Diagnosis of Bronchiectasis
Figure 6: Patient Journey
Figure 7: Total Diagnosed Prevalent Cases of NCFB in the 7MM (2022-2036)
Figure 8: Total Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in the 7MM (2022-2036)
Figure 9: Total Diagnosed Prevalent Cases of NCFB in the US (2022-2036)
Figure 10: Gender-specific Diagnosed Prevalent Cases of NCFB in the US (2022-2036)
Figure 11: Severity-specific Diagnosed Prevalent Cases of NCFB in the US (2022-2036)
Figure 12: Etiology-specific Diagnosed Prevalent Cases of NCFB in the US (2022-2036)
Figure 13: Microbiology of NCFB Patients in the US (2022-2036)
Figure 14: Total Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in the US (2022-2036)
Figure 15: Gender-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in the US (2022-2036)
Figure 16: Age-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in the US (2022-2036)
Figure 17: Microbiology of Cystic Fibrosis Bronchiectasis Patients in the US (2022-2036)
Figure 18: Total Diagnosed Prevalent Cases of NCFB in EU4 and the UK (2022-2036)
Figure 19: Gender-specific Diagnosed Prevalent Cases of NCFB in EU4 and the UK (2022-2036)
Figure 20: Severity-specific Diagnosed Prevalent Cases of NCFB in EU4 and the UK (2022-2036)
Figure 21: Etiology-specific Diagnosed Prevalent Cases of NCFB in EU4 and the UK (2022-2036)
Figure 22: Microbiology of NCFB Patients in EU4 and the UK (2022-2036)
Figure 23: Total Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in EU4 and the UK (2022-2036)
Figure 24: Gender-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in EU4 and the UK (2022-2036)
Figure 25: Age-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in EU4 and the UK (2022-2036)
Figure 26: Microbiology of Cystic Fibrosis Bronchiectasis Patients in EU4 and the UK (2022-2036)
Figure 27: Total Diagnosed Prevalent Cases of NCFB in Japan (2022-2036)
Figure 28: Gender-specific Diagnosed Prevalent Cases of NCFB in Japan (2022-2036)
Figure 29: Severity-specific Diagnosed Prevalent Cases of NCFB in Japan (2022-2036)
Figure 30: Etiology-specific Diagnosed Prevalent Cases of NCFB in Japan (2022-2036)
Figure 31: Microbiology of NCFB Patients in Japan (2022-2036)
Figure 32: Total Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in Japan (2022-2036)
Figure 33: Gender-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in Japan (2022-2036)
Figure 34: Age-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis in Japan (2022-2036)
Figure 35: Microbiology of Cystic Fibrosis Bronchiectasis Patients in Japan (2022-2036)

Bronchiectasis Epidemiology Forecast - 2036

Description

Table of Contents

List of Tables

Bronchiectasis Insights and Trends

Geography Covered:

Bronchiectasis Epidemiology

Scope of the Report:

Report Insights

Report Key Strengths

FAQs:

Reasons to Buy:

Table of Contents

1. Key Insights

2. Report Introduction

3. Epidemiology Overview at a Glance

4. Epidemiology Forecast Methodology

5. Executive Summary

6. Disease Background and Overview: Bronchiectasis

7. Patient Journey

8. Epidemiology and Patient Population

9. Key Opinion Leaders' Views

10. Appendix

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

List of Tables

List of Figures